Hemangioendothelioma

Hemangioendothelioma is a rare tumor that arises from the endothelial cells lining blood and lymphatic vessels. It is a vascular tumor characterized by the formation of abnormal vascular structures and can manifest as either benign or malignant forms. Hemangioendothelioma most commonly occurs in soft tissues and internal organs such as the liver, lungs, and spleen. There are several classifications of the disease, including classes based on its cellular differentiation and tumor location. The clinical course of hemangioendothelioma can vary greatly from asymptomatic to aggressive, making diagnosis and treatment challenging.

History of the disease and interesting historical facts

Hemangioendothelioma was first described in the medical literature in the early 20th century. One of the first significant studies of this disease was the description of cases of hemangioendothelioma in children in the 1970s by Dr. A. J. Fened. This discovery led to further study of the pathophysiology and clinical aspects of the disease. An interesting historical detail is that for decades, doctors incorrectly interpreted hemangioendothelioma as ordinary hemangiomas, which made proper diagnosis and treatment difficult. Modern research has corrected the understanding of this disease, dividing it into several subtypes and defining different rules for diagnosis and treatment.

Epidemiology

According to current data, hemangioendotheliomas account for only about 1-2% of all vascular tumors, indicating their rarity in clinical practice. The disease can be detected in both children and adults, although in most cases the diagnosis is made between the ages of 20 and 50. The high diagnostic rate in recent decades is due to the improvement of imaging methods and histological analysis. According to studies, women suffer from hemangioendotheliomas 2-3 times more often than men. Examples of individual cases indicate that the incidence of hemangioendotheliomas may vary depending on the geographic region and ethnicity, which requires further study.

Genetic predisposition to this disease

To date, research has shown that hemangioendothelioma may have some genetic predisposition. Certain mutations in genes responsible for angiogenesis and cell proliferation may contribute to the development of this disease. In particular, the VEGF (vascular endothelial growth factor) and RAS (proton cogene) genes are actively studied for their role in the pathogenesis of hemangioendothelioma. One recent study showed that about 30% patients with hemangioendothelioma have mutations in the TP53 gene, which is necessary for the regulation of the cell cycle and apoptosis. These data emphasize the importance of genetic diagnostics in the process of identifying the risk of developing the disease and understanding its mechanism.

Risk factors for the development of this disease

There are several risk factors that may be associated with the development of hemangioendothelioma:

• Physical factors: predisposition to soft tissue trauma or surgical interventions in an area where a tumor may subsequently develop.
• Chemical factors: exposure to certain carcinogens, such as carcinogenic compounds found in tobacco smoke.
• Immune disorders: Having conditions that weaken the immune system may increase the risk of developing vascular tumors.
• Associated diseases: Certain underlying diseases, such as lymphedema, may contribute to the formation of hemangioendothelioma.

Diagnosis of this disease

Diagnosis of hemangioendothelioma includes several stages and methods, including:

• Main symptoms: most often, patients complain of a painful or painless lump in the area of the tumor, which may be accompanied by swelling.
• Laboratory tests: biopsy followed by histological analysis is the gold standard in the diagnosis of hemangioendothelioma.
• Radiological examinations: the use of MRI and CT allows visualization of the tumor and assessment of its size, location and possible metastases.
• Other diagnostic methods: Ultrasound can be used for preliminary evaluation, especially in case of liver hemangioendothelioma.
• Differential diagnosis: It is important to distinguish hemangioendothelioma from other vascular tumors and benign lesions such as hemangiomas.

Treatment

Treatment for hemangioendothelioma may vary depending on the patient's age, stage of the disease, and the presence of metastases. Common treatments include:

• General treatment: depends on the type of hemangioendothelioma, its location, and the general health of the patient.
• Pharmacological treatment: The use of antineoplastic agents such as vincristine and paclitaxel has appeared successful in treating some forms.
• Surgical treatment: Surgery to remove the tumor is a commonly used method, especially if the hemangioendothelioma is localized and has not metastasized.
• Other treatments: Radiation therapy may be used in cases of inoperable forms or as adjuvant therapy after surgery.

List of medications used to treat this disease

Drugs that may be used to treat hemangioendothelioma include:

• Vincristine
• Paclitaxel
• Doxorubicin
• Tamoxifen
• Reserpine

Disease monitoring

Monitoring of hemangioendothelioma is necessary to assess the dynamics of the patient's condition and the effectiveness of treatment. Control stages may include:

• Routine orders for radiological imaging tests, such as MRI or ultrasound, to assess the size of the tumor.
• Laboratory tests to monitor the patient's general health and blood condition.
• The prognosis varies depending on the type of hemangioendothelioma: benign forms have a good prognosis, while malignant ones may require more intensive treatment.
• Complications may include recurrence of the disease, metastases, and in some cases, death if not treated promptly.

Age-related features of the disease

Hemangioendothelioma can present differently depending on the patient’s age. Children are more likely to have more benign forms, such as infantile hemangioendotheliomas, which may regress on their own. Adult patients are more likely to have malignant forms of the tumor, which requires a more aggressive approach to treatment. In older patients, the disease may be associated with other comorbid conditions, which also affects the choice of treatment and monitoring methods.

Questions and Answers

• What is hemangioendothelioma? Hemangioendothelioma is a tumor that develops from endothelial cells and can manifest itself in both benign and malignant forms.
• What symptoms may indicate hemangioendothelioma? Symptoms may include painless or painful lumps, swelling, and sometimes organ dysfunction.
• How is hemangioendothelioma diagnosed? Diagnosis includes biopsy, radiological studies and clinical examination.
• How is hemangioendothelioma treated? Treatment may include surgery, chemotherapy, and in some cases radiation therapy.
• What is the prognosis for hemangioendothelioma? The prognosis depends on the type of hemangioendothelioma, the stage of the disease and the general condition of the patient.

Dr. Oleg Korzhikov, leading oncologist: “If you or your child has been diagnosed with hemangioendothelioma, it is important to see a specialist as soon as possible. Early diagnosis and intervention will help achieve the best results. In addition, pay attention to any changes in health - this can be a key point in the treatment process. Do not forget about regular check-ups and following the doctor's recommendations, as some forms of tumors can be asymptomatic, but up to a certain point remain dangerous.”